{
  "docId": "019dd923-5e88-73ef-bd5c-fd5012384ae3",
  "docSlug": "bf350dd574c19997",
  "documentTitle": "2021 Air Street Capital The State of AI Report 2021",
  "authorId": "AirStreetCapital",
  "authorName": "Air Street Capital",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "vc_research",
  "sourceTypeLabel": "VC research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.777,
  "pageNumber": 93,
  "pageCount": 188,
  "prevPage": 92,
  "nextPage": 94,
  "slideType": "case_study",
  "function": "illustrate_case",
  "density": "dense",
  "nDataPoints": 22,
  "notes": "The slide highlights Exscientia's performance metrics (compounds synthesized and time-to-hit) against industry benchmarks.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "bar_chart_vertical",
    "bar_chart_stacked",
    "logo_grid"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5c-fd5012384ae3/93",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5c-fd5012384ae3",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5c-fd5012384ae3.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5c-fd5012384ae3#slide-93",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "10x fewer synthesized compounds to deliver a candidate; 12 months target-to-hit vs. 54 months industry average.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-47c4-7719-a20a-2e9ada7ead5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.52,
        "y": 0.55
      },
      "kind": "chart",
      "text": "12 months target-to-hit vs. 54 months industry average",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa6f3110-3241-4112-8c6d-2839d82c7fdc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "chart",
      "text": "10x fewer synthesized compounds to deliver a candidate",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70e74b4d-006b-4b1d-b246-c7218ecafcc4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Time to discovery: 12 months",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-47c4-7719-a20a-302acbae6aff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "British AI-first drug discovery company, Exscientia, originated the world's first 3 AI-designed drugs into Phase 1 human testing and IPO'd on the NASDAQ on 1 October 2021 at a >$3B valuation. Exscientia is now the UK's largest biotech and the 3rd largest biopharma company in the UK next to GSK and AstraZeneca. The company has a further 4 more drug candidates currently undergoing advanced profiling for submission of investigational new drug applications, in addition to more than 25 active projects in total.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26f6beae-51df-4196-a4e3-a39d8a80b348",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "title",
      "text": "2020 Prediction: An AI-first drug discovery companies IPOs or is acquired for $1B",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43b98059-4a80-464f-99e4-ae4f344295e8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Callback",
      "slug": "callback",
      "agent": "Storyteller",
      "layer": "loop",
      "matchId": "019dd95a-1054-7078-98b6-cd2752a2d899",
      "evidence": "Title '2020 Prediction: An AI-first drug discovery company IPOs…'",
      "confidence": 88
    },
    {
      "name": "Concrete Language",
      "slug": "concrete-language",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "019dd95a-1054-7078-98b6-d0c3f2f08377",
      "evidence": "12 months target-to-hit vs 54 industry average.",
      "confidence": 78
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 152,
      "from": 5,
      "beatId": "019dd95a-0682-776c-8e35-0affbadec38e",
      "arcName": "The Triple Take",
      "arcSlug": "triple-take",
      "beatName": "The Facts (What)",
      "beatSlug": "triple-take-the-facts-what",
      "evidence": "Definitions p.5-6, Exec Summary p.7, then Sections 1-3 catalog evidence.",
      "position": 1,
      "confidence": 78,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    },
    {
      "to": 152,
      "from": 10,
      "beatId": "019dd95a-0682-776c-8e35-1b3ee3a1c012",
      "arcName": "The Mountain",
      "arcSlug": "mountain",
      "beatName": "Rising Action",
      "beatSlug": "mountain-rising-action",
      "evidence": "Three sections accumulating evidence of accelerating progress.",
      "position": 2,
      "confidence": 55,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 97,
      "from": 93,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "019dd95a-07fe-70ce-8d3d-6d94b8e8790f",
      "evidence": "Multiple case studies validating the 2020 IPO prediction with applied biology proof.",
      "position": 12,
      "objective": "Show AI delivering in drug discovery",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 78,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}